Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTOK0LR)

• DTT Name: Toll-like receptor (TLR)
• Synonyms: Toll-like receptor
• Gene Name: TLR
• DTT Type: Clinical trial target; [1]
• UniProt ID: NOUNIPROTAC
• TTD ID: T41963

Molecular Interaction Atlas (MIA) of This DTT

4 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BDB001	DMKFJXP	Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
DPV-001	DMMC3XR	Non-small-cell lung cancer	2C25.Y	Phase 2	[1]
IMO-8400	DMDPNCJ	Rheumatoid arthritis	FA20	Phase 2	[3]
IMO-9200	DMEHWPC	Autoimmune disease	4A40-4A45	Phase 1	[4]

12 Patented Agent(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID30280939-Compound-US20170128558	DMM83WL	Malaria	1F40-1F45	Patented	[5]
PMID30280939-Compound-US20179642901	DMPVW2Q	Malaria	1F40-1F45	Patented	[5]
PMID30280939-Compound-WO2005070959	DM6VP5K	N. A.	N. A.	Patented	[5]
PMID30280939-Compound-WO200606195	DMLVSEK	N. A.	N. A.	Patented	[5]
PMID30280939-Compound-WO2008009652	DM7DG0M	Malaria	1F40-1F45	Patented	[5]
PMID30280939-Compound-WO2009082440	DMXRHCJ	N. A.	N. A.	Patented	[5]
PMID30280939-Compound-WO2013119856	DMRB7LI	N. A.	N. A.	Patented	[5]
PMID30280939-Compound-WO2013148426	DMUKIEJ	Malaria	1F40-1F45	Patented	[5]
PMID30280939-Compound-WO2013148427	DM4Z2KY	N. A.	N. A.	Patented	[5]
PMID30280939-Compound-WO2015035128	DM4ILAK	N. A.	N. A.	Patented	[5]
PMID30280939-Compound-WO2015091734	DM5K3DF	Malaria	1F40-1F45	Patented	[5]
PMID30280939-Compound-WO2015150568	DMGCE3Z	N. A.	N. A.	Patented	[5]

1 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ONO-4007	DMIZXFJ	Immune System disease	4A01-4B41	Discontinued in Phase 2	[6]

References

• [1] UbiVac's DRibble, autophagosome-enriched vaccines: Applications for cancer and infectious disease. UbiVac. 2013.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847.
• [6] Toll-like receptors TLR2 and TLR4 initiate the innate immune response of the renal tubular epithelium to bacterial products. Clin Exp Immunol. 2006 August; 145(2): 346-356.